Skip to main content

Table 2 Main Preoperative Characteristics of the Study Population.

From: Thrombotic gene polymorphisms and postoperative outcome after coronary artery bypass graft surgery

 

Study population

(n = 220)

FVL 1691 G/G

(n = 196)

FVL 1691 G/A

(n = 24)

p value*

PT 20210 G/G

(n = 212)

PT 20210 G/A

(n = 8)

p value**

ACE I/I

and

ACE I/D

(n = 124)

ACE D/D+

(n = 57)

p value***

Age (yrs), mean ± SD

62.5 ± 10.2

62.5 ± 10.2

62.3 ± 10.6

NS

62.7 ± 10.2

57.6 ± 8.5

NS

62.0 ± 9.7

63.2 ± 10.5

NS

Female sex, n (%)

58 (26.4)

54 (24.6)

4 (16.7)

NS

56 (26.4)

2 (25)

NS

29 (23.4)

13 (22.8)

NS

Body surface area (m2), mean ± SD

1.8 ± 0.2

1.8 ± 0.2

1.8 ± 0.1

NS

1.8 ± 0.2

1.8 ± 0.2

NS

1.8 ± 0.2

1.79 ± 0.14

NS

Hypertension, n (%)

89 (40.5)

80 (40.8)

9 (37.5)

NS

88 (41.5)

1 (12.5)

NS

46 (37.1)

34 (59.7)

0.004

Diabetes, n (%)

118 (53.6)

107 (54.6)

11 (45.8)

NS

113 (53.3)

5 (62.5)

NS

68 (54.8)

29 (50.9)

NS

Hypercholesterolemia, n (%)

94 (42.7)

83 (42.4)

11 (45.8)

NS

92 (43.4)

2 (25)

NS

59 (47.6)

28 (49.1)

NS

Smoking, n (%)

122 (55.5)

107 (54.6)

15 (62.5)

NS

122 (57.6)

2 (25)

NS

66 (53.2)

35 (61.4)

NS

Previous stroke, n (%)

3 (1.4)

3 (1.5)

0

NS

3 (1.4)

0

NS

1 (0.8)

1 (1.8)

NS

Peripheral arterial disease, n (%)

25 (11.4)

22 (11.2)

3 (12.5)

NS

24 (11.3)

1 (12.5)

NS

10 (8.1)

13 (22.8)

0.006

Previous hospital admission for MI, n (%)

52 (23.6)

43 (21.9)

9 (37.5)

NS

51 (24.1)

1 (12.5)

NS

26 (21.0)

23 (40.4)

0.007

COPD, n (%)

32 (14.6)

28 (12.7)

4 (16.7)

NS

32 (15.1)

0

NS

17 (13.7)

12 (21.1)

NS

Creatinine > 2.3 mg/dL, n (%)

7 (3.2)

5 (2.6)

2 (8.3)

NS

6 (2.8)

1 (12.5)

NS

1 (0.8)

2 (3.5)

NS

Catheter lab emergency, n (%)

5 (2.6)

5 (2.6)

0

NS

4 (1.9)

1 (12.5)

NS

0

2 (3.5)

NS

Number of diseased coronary arteries, n (%)

2.4 ± 0.7

2.4 ± 0.7

2.4 ± 0.7

NS

2.4 ± 0.7

2.4 ± 0.9

NS

2.4 ± 0.71

2.5 ± 0.7

NS

Totally Occluded Coronary Arteries, n (%)

0.1 ± 0.3

0.1 ± 0.2

0.46 ± 0.7

< 0.001

0.08 ± 0.3

0.3 ± 0.5

< 0.001

0.1 ± 0.35

0.1 ± 0.3

NS

Left ventricular aneurysm, n (%)

10 (4.6)

5 (2.6)

5 (20.8)

0.002

9 (4.3)

1 (12.5)

NS

8 (6.5)

1 (1.8)

NS

Intracardiac thrombus, n (%)

2 (0.9)

2 (0.9)

0

NS

2 (0.9)

0

NS

1 (0.8)

1 (1.8)

NS

Ischemic mitral regurgitation, n (%)

19 (8.6)

16 (8.2)

3 (12.5)

NS

17 (8.0)

2 (25)

NS

15 (12.1)

4 (7.0)

NS

LVEF (%) mean ± SD

52.8 ± 9.9

53.3 ± 9.9

49.3 ± 9.0

NS

52.7 ± 10.0

55.9 ± 4.9

NS

53.6 ± 10.1

52.84 ± 10.1

NS

EuroScore, mean ± SD

1.3 ± 1.3

1.9 ± 1.5

1.9 ± 1.5

NS

2.0 ± 1.5

1.9 ± 1.5

NS

1.85 ± 1.5

1.93 ± 1.4

NS

  1. Values are mean ± SD or percentage of patients, FVL indicates factor V Leiden; PT 20210, prothrombin/factor II; ACE-ins/del, angiotensin-converting enzyme gene insertion/deletion polymorphism; COPD, chronic obstructive pulmonary disease; LVEF, left ventricular ejection fraction; NS, Non-significant. The study population of ACE D/D genotype consisted of 181 patients.
  2. * FVL 1691G/G compared with FVL 1691 G/A polymorphism; ** PT 20210 G/G compared with PT 20210 G/A polymorphism; *** ACE I/I and ACE I/D group compared with ACE D/D polymorphism group.